Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zalutumumab in recurrent/metastatic SCCHN
NCT00093041Phase 2Completed
- Sponsor
- Genmab
- Start
- Dec 2003
- Primary completion
- Jan 2005
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of zalutumumab in squamous cell carcinoma of the head and neck (HNSCC), sponsored by Genmab. Started Dec 2003; status: completed.
02
Drugs
zalutumumab
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT00093041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00093041.